Human COMP/Thrombospondin-5 Alexa Fluor™ Plus 680-conjugated Antibody
R&D Systems, part of Bio-Techne | Catalog # AF3134AFP680
Key Product Details
Species Reactivity
Applications
Label
Antibody Source
Product Specifications
Specificity
Clonality
Host
Isotype
Applications
Western Blot
Neutralization
Background: COMP/Thrombospondin-5
Cartilage Oligomeric Matrix Protein (COMP), also known as Thrombospondin-5, is a 110 kDa multidomain calcium binding protein that associates with other extracellular matrix molecules. Thrombospondin-1 and -2 constitute subgroup A and form homotrimers, whereas Thrombospondin-3, -4, and COMP constitute subgroup B and form homopentamers (1-4). The human COMP cDNA encodes a 757 amino acid (aa) precursor that includes a 20 aa signal sequence followed by a non-collagenous
coiled‑coil domain, four EGF-like repeats, seven TSP type-3 repeats, and a globular TSP C-terminal domain (5). Human COMP shares 86-93% aa sequence identity with rat, mouse, equine, bovine, and canine COMP. Within the TSP type-3 repeats and TSP C-terminal domain, human COMP shares 60%, 61%, 74%, and 80% aa sequence identity with human Thrombospondin-1, -2, -3, and -4, respectively. The coiled coil domain mediates the association of COMP into disulfide-linked homopentamers with a central hub and peripheral globular domains connected by flexible strands (6, 7). An axial pore is formed by the coiled coil assembly and binds vitamin D3 which is involved in bone and cartilage metabolism (8). An RGD sequence in the third TSP type-3 repeat mediates chondrocyte attachment via Integrin alpha5 beta1, although when reduced and in the absence of calcium, attachment is mediated via Integrin alphaV beta3 (9). COMP is upregulated in rheumatoid arthritis and osteoarthritis, hepatocellular carcinomas, chronic pancreatitis, and pancreatic carcinomas (10-12). Elevated circulating COMP levels are used as a biomarker for early onset of some skeletal disorders (10). Several mutations are associated with skeletal dysplasias, and the most common, a point mutation in the third TSP type-3 repeat, results in diminished calcium binding ability (13, 14).
References
- Adams, J.C. and J. Lawler (2004) Int J. Biochem. Cell Biol. 36:961.
- Posey, K.L. et al. (2004) Int. J. Biochem. Cell Biol. 36:1005.
- Adams, J.C. (2004) Int. J. Biochem. Cell Biol. 36:1102.
- Mann, H.H. et al. (2004) J. Biol. Chem. 279:25294.
- Newton, G. et al. (1994) Genomics, 24:435.
- DiCesare, P. et al. (1995) J. Orthopaedic Res. 13:422.
- Efimov, V.P. et al. (1994) FEBS Lett. 341:54.
- Ozbek, S. et al. (2002) EMBO J. 21:5960.
- Chen, F.H. et al. (2005) J. Biol. Chem. 280:32655.
- Wislowska, M. and B. Jablonska (2005) Clin. Rheumatol. 24:278.
- Xiao, Y. et al. (2004) J. Gastroenterol. Hepatol. 19:296.
- Liao, Q. et al. (2003) Scand. J. Gastroenterol. 38:207.
- Kennedy, J. et al. (2005) Eur. J. Hum. Genet. 13:547.
- Hou, J. et al. (2000) Cell Calcium 27:309.
Long Name
Alternate Names
Gene Symbol
UniProt
Additional COMP/Thrombospondin-5 Products
Product Specific Notices
This product is provided under an intellectual property license from Life Technologies Corporation. The transfer of this product is conditioned on the buyer using the purchased product solely in research conducted by the buyer, excluding contract research or any fee for service research, and the buyer must not (1) use this product or its components for (a) diagnostic, therapeutic or prophylactic purposes; (b) testing, analysis or screening services, or information in return for compensation on a per-test basis; or (c) manufacturing or quality assurance or quality control, and/or (2) sell or transfer this product or its components for resale, whether or not resold for use in research. For information on purchasing a license to this product for purposes other than as described above, contact Life Technologies Corporation, 5781 Van Allen Way, Carlsbad, CA 92008 USA or outlicensing@thermofisher.com.
For research use only